INKON Life Technology Co., Ltd.

SZSE:300143 Stock Report

Market Cap: CN¥6.4b

INKON Life Technology Valuation

Is 300143 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 300143 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 300143 (CN¥9.53) is trading above our estimate of fair value (CN¥2.98)

Significantly Below Fair Value: 300143 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 300143?

Key metric: As 300143 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 300143. This is calculated by dividing 300143's market cap by their current earnings.
What is 300143's PE Ratio?
PE Ratio67.9x
EarningsCN¥88.93m
Market CapCN¥6.40b

Price to Earnings Ratio vs Peers

How does 300143's PE Ratio compare to its peers?

The above table shows the PE ratio for 300143 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average81.9x
002219 New Journey Health Technology GroupLTD
176.9xn/aCN¥9.4b
301293 Sanbo Hospital Management Group
81.5xn/aCN¥9.5b
301267 Huaxia Eye Hospital GroupLtd
32.8x22.4%CN¥18.3b
300015 Aier Eye Hospital Group
36.6x15.3%CN¥139.6b
300143 INKON Life Technology
67.9x33.3%CN¥6.4b

Price-To-Earnings vs Peers: 300143 is good value based on its Price-To-Earnings Ratio (67.9x) compared to the peer average (81.9x).

Price to Earnings Ratio vs Industry

How does 300143's PE Ratio compare vs other companies in the CN Healthcare Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No more companies available in this PE range
300143 67.9xIndustry Avg. 34.5xNo. of Companies7PE020406080100+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 300143 is expensive based on its Price-To-Earnings Ratio (67.9x) compared to the CN Healthcare industry average (34.5x).

Price to Earnings Ratio vs Fair Ratio

What is 300143's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

300143 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio67.9x
Fair PE Ratio33.2x

Price-To-Earnings vs Fair Ratio: 300143 is expensive based on its Price-To-Earnings Ratio (67.9x) compared to the estimated Fair Price-To-Earnings Ratio (33.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Shenzhen Lifotronic Technology

CN¥7.1b

Research, develops, manufactures, and markets medical devices for diagnostics, clinical medicine, skin, and human health related purposes in China.

688389

CN¥15.53

7D

-5.8%

1Y

-34.9%

Innovita Biological Technology

CN¥6.0b

Engages in the research and development, manufacturing, marketing, and sales of POCT rapid diagnostic products.

688253

CN¥44.03

7D

2.4%

1Y

46.3%

iRay Technology

CN¥16.1b

Develops, manufactures, and sells flat panel X-ray detectors for use in medical, dental, oncology, veterinary, security, and industrial imaging applications in China and internationally.

688301

CN¥108.85

7D

-3.0%

1Y

-32.1%